- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00445367
Biobank For MS And Other Demyelinating Diseases
April 18, 2024 updated by: Accelerated Cure Project for Multiple Sclerosis
Large-scale, Multi-disciplinary Sample and Data Repository for Multiple Sclerosis and Related Demyelinating Diseases
To establish a large, longitudinal collection of high quality samples and data from subjects with MS, selected other demyelinating diseases (Transverse Myelitis (TM), Neuromyelitis Optica (NMO) or Devic's, Acute Disseminated Encephalomyelitis (ADEM), and Optic Neuritis (ON)), and related and unrelated unaffected controls.
Samples and data will be available as a shared resource to scientists researching the causes, sub-types, and biomarkers of MS and related demyelinating diseases.
Study Overview
Status
Active, not recruiting
Study Type
Observational
Enrollment (Actual)
3226
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85013
- Barrow Neurological Institute
-
-
California
-
Stanford, California, United States, 94305
- Stanford University
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- The Rocky Mountain MS Center at Anschutz Medical Campus at UC Denver
-
-
Georgia
-
Atlanta, Georgia, United States, 30309
- Shepherd Center
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Johns Hopkins
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Beth Israel Deaconess
-
Worcester, Massachusetts, United States, 01605
- University of Massachusetts Medical School
-
-
New York
-
New York, New York, United States, 10019
- Multiple Sclerosis Research Center of New York
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- The Ohio State University
-
-
Texas
-
Dallas, Texas, United States, 76051
- University of Texas Southwestern Medical Center at Dallas
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Sampling Method
Non-Probability Sample
Study Population
Subjects with MS, selected other demyelinating diseases (Transverse Myelitis (TM), Neuromyelitis Optica (NMO) or Devic's, Acute Disseminated Encephalomyelitis (ADEM), and Optic Neuritis (ON)), and related and unrelated unaffected controls.
Description
Inclusion Criteria:
- age 18+ able to give informed consent or individuals younger than 18 with parental permission and able to give assent
- willing to provide up to 110 ml (50 ml for < 18 years old) of blood via venipuncture
- experienced at least one CNS demyelinating event characteristic of MS, TM, NMO, ADEM, or ON
Exclusion Criteria:
- history of blood borne pathogens
- allogeneic bone marrow transplant
- clinical or radiological evidence of stroke, meningitis, or other well characterized diseases of the nervous system (with the exception of MS, TM, NMO, ADEM, or ON).
- weight less than 37 pounds
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Control
|
Case
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Benjamin Greenberg, M.D., M.H.S., University of Texas
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2006
Primary Completion (Estimated)
October 1, 2026
Study Completion (Estimated)
October 1, 2036
Study Registration Dates
First Submitted
March 8, 2007
First Submitted That Met QC Criteria
March 8, 2007
First Posted (Estimated)
March 9, 2007
Study Record Updates
Last Update Posted (Estimated)
April 19, 2024
Last Update Submitted That Met QC Criteria
April 18, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Infections
- Immune System Diseases
- Neoplasms
- Demyelinating Autoimmune Diseases, CNS
- Autoimmune Diseases of the Nervous System
- Autoimmune Diseases
- Neoplasms by Site
- Eye Diseases
- Disease Attributes
- Neuromuscular Diseases
- Central Nervous System Infections
- Neurodegenerative Diseases
- Peripheral Nervous System Diseases
- Spinal Cord Diseases
- Nervous System Neoplasms
- Optic Nerve Diseases
- Cranial Nerve Diseases
- Paraneoplastic Syndromes, Nervous System
- Paraneoplastic Syndromes
- Leukoencephalopathies
- Chronic Disease
- Neuroinflammatory Diseases
- Post-Infectious Disorders
- Multiple Sclerosis
- Sclerosis
- Neuritis
- Optic Neuritis
- Neuromyelitis Optica
- Demyelinating Diseases
- Myelitis
- Myelitis, Transverse
- Encephalomyelitis
- Encephalomyelitis, Acute Disseminated
Other Study ID Numbers
- ACP-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsRecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
University of California, San FranciscoUnited States Department of DefenseRecruitingMultiple Sclerosis, Chronic Progressive | Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis (MS) | Multiple Sclerosis Relapse | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis Brain Lesion | Multiple Sclerosis BenignUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Queen Mary University of LondonTakeda Pharmaceuticals International, Inc.RecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited Kingdom
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States